ID
32085
Descrição
Study ID: 103992 Clinical Study ID: 103992 Study Title: Evaluate immunogenicity, reactogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00139334 https://clinicaltrials.gov/ct2/show/NCT00139334 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Rotavirus Vaccine Trade Name: Rotarix Study Indication: Haemophilus influenzae type b; Neisseria Meningitidis This form is for documentation of concomitant vaccinations (e.g., BCG) excluding protocol-planned vaccinations (HRV vaccine, OPV, DTPw-HB in Visits 1-5), as well as contraindicated (immune globulins) and other medication having been administered.
Link
https://clinicaltrials.gov/ct2/show/NCT00139334
Palavras-chave
Versões (1)
- 17/10/2018 17/10/2018 - Sarah Riepenhausen
Titular dos direitos
GlaxoSmithKline
Transferido a
17 de outubro de 2018
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
GSK Biologicals' oral HRV vaccine given with OPV in infants NCT00139334
Concomitant Vaccination and (contraindicated) Medication
- StudyEvent: ODM
Descrição
Concomitant Vaccination
Alias
- UMLS CUI-1
- C0042196
- UMLS CUI-2
- C2347852
Descrição
If yes, please record concomitant vaccination with trade name and/or generic name, route and vaccine administration date in the following itemgroup.
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C0042196
- UMLS CUI [1,2]
- C2347852
Descrição
Concomitant Vaccination Characteristics
Alias
- UMLS CUI-1
- C0042196
- UMLS CUI-2
- C2347852
- UMLS CUI-3
- C2348235
Descrição
Trade / (Generic) Name
Tipo de dados
text
Alias
- UMLS CUI [1,1]
- C2360065
- UMLS CUI [1,2]
- C0042210
Descrição
Route of Administration
Tipo de dados
text
Alias
- UMLS CUI [1,1]
- C0013153
- UMLS CUI [1,2]
- C0042210
Descrição
Administration Date
Tipo de dados
date
Alias
- UMLS CUI [1,1]
- C0042210
- UMLS CUI [1,2]
- C1533734
- UMLS CUI [1,3]
- C0011008
Descrição
Commentary field for GSK
Tipo de dados
text
Alias
- UMLS CUI [1,1]
- C0008961
- UMLS CUI [1,2]
- C0947611
Descrição
Contraindicated Medication / Medication
Alias
- UMLS CUI-1
- C0013227
- UMLS CUI-2
- C0522473
- UMLS CUI-3
- C0525058
Descrição
All concomitant medication, with the exception of vitamins and/or dietary supplements, administered at ANY time during the period starting with administration of each dose of study vaccine (Visit 3) and ending at Visit 6 are to be recorded with generic name of the medication (trade names are allowed for combination drugs, i.e. multi-component drugs), medical indication, total daily dose, route of administration, start and end dates of treatment. Any treatments and/or medications specifically contraindicated, e.g., any immunoglobulins, other blood products and any immune modifying drugs administered since birth or at any time during the study period are to be recorded with generic name of the medication (trade names are allowed for combination drugs only), medical indication, total daily dose, route of administration, start and end dates of treatment. Concomitant medication administered for the treatment of an AE or SAE within the follow-up period for adverse events must be recorded in the CRF with generic name of the medication (trade names are allowed for combination drugs only), medical indication (including which AE/SAE), total daily dose, route of administration, start and end dates of treatment. If yes, please complete the following item group.
Tipo de dados
boolean
Alias
- UMLS CUI [1]
- C2347852
Descrição
Medication Characteristics
Alias
- UMLS CUI-1
- C2347852
- UMLS CUI-2
- C2348235
Descrição
Trade / (Generic) Name
Tipo de dados
text
Alias
- UMLS CUI [1]
- C2360065
Descrição
Medical indication
Tipo de dados
text
Alias
- UMLS CUI [1]
- C3146298
Descrição
A prophylactic medication is a medication administered in the absence of ANY symptom and in anticipation of a reaction to the vaccination (e.g. an anti-pyretic is considered to be prophylactic when it is given in the absence of fever [rectal temperature < 38°C] and any other symptom, to prevent fever from occurring). Any concomitant medication administered prophylactically in anticipation of reaction to the vaccination must be recorded in the CRF with generic name of the medication (trade names are allowed for combination drugs only), total daily dose, route of administration, start and end dates of treatment and coded as ‘Prophylactic’.
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C0199176
- UMLS CUI [1,2]
- C3146298
Descrição
Total daily dose
Tipo de dados
text
Alias
- UMLS CUI [1]
- C2348070
Descrição
Route of Administration
Tipo de dados
text
Alias
- UMLS CUI [1]
- C0013153
Descrição
Administration Date
Tipo de dados
date
Alias
- UMLS CUI [1,1]
- C1533734
- UMLS CUI [1,2]
- C0011008
Descrição
Start date of Administration
Tipo de dados
date
Alias
- UMLS CUI [1]
- C0808070
Descrição
If the administration ended during the time of the study.
Tipo de dados
date
Alias
- UMLS CUI [1]
- C0806020
Descrição
Ongoing Administration
Tipo de dados
boolean
Alias
- UMLS CUI [1]
- C2826666
Descrição
Commentary field for GSK
Tipo de dados
text
Alias
- UMLS CUI [1,1]
- C0008961
- UMLS CUI [1,2]
- C0947611
Similar models
Concomitant Vaccination and (contraindicated) Medication
- StudyEvent: ODM
C2347852 (UMLS CUI-2)
C2347852 (UMLS CUI [1,2])
C2347852 (UMLS CUI-2)
C2348235 (UMLS CUI-3)
C0042210 (UMLS CUI [1,2])
C0042210 (UMLS CUI [1,2])
C1533734 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0947611 (UMLS CUI [1,2])
C0522473 (UMLS CUI-2)
C0525058 (UMLS CUI-3)
C2348235 (UMLS CUI-2)
C3146298 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0947611 (UMLS CUI [1,2])